These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1168 related articles for article (PubMed ID: 31539077)

  • 21. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.
    Jiang W; Cheng H; Yu L; Zhang J; Wang Y; Liang Y; Lou F; Wang H; Cao S
    Cancer Med; 2023 Mar; 12(6):6649-6658. PubMed ID: 36440695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
    Shepherd FA; Lacas B; Le Teuff G; Hainaut P; Jänne PA; Pignon JP; Le Chevalier T; Seymour L; Douillard JY; Graziano S; Brambilla E; Pirker R; Filipits M; Kratzke R; Soria JC; Tsao MS;
    J Clin Oncol; 2017 Jun; 35(18):2018-2027. PubMed ID: 28453411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-small-cell lung cancer patients harboring
    Zhang C; Wang K; Lin J; Wang H
    Future Oncol; 2022 Sep; 18(27):3031-3041. PubMed ID: 36065989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
    Front Immunol; 2021; 12():667875. PubMed ID: 34603277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
    Lu C; Dong XR; Zhao J; Zhang XC; Chen HJ; Zhou Q; Tu HY; Ai XH; Chen XF; An GL; Bai J; Shan JL; Wang YN; Yang SY; Liu X; Zhuang W; Wu HT; Zhu B; Xia XF; Chen RR; Gu DJ; Xu HM; Wu YL; Yang JJ
    J Hematol Oncol; 2020 Apr; 13(1):37. PubMed ID: 32295619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.
    Liu M; Yang M; Zhang B; Xia S; Zhao J; Yan L; Ren Y; Guo H; Zhao J
    J Mol Med (Berl); 2024 Jul; 102(7):899-912. PubMed ID: 38739269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
    Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
    Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
    Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
    Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.
    Chen J; Zheng Q; Wang J; Zhang X; Lv Y
    Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Jiao XD; Qin BD; You P; Cai J; Zang YS
    Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
    Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.
    Mazzotta M; Filetti M; Occhipinti M; Marinelli D; Scalera S; Terrenato I; Sperati F; Pallocca M; Rizzo F; Gelibter A; Botticelli A; Scafetta G; Di Napoli A; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Fanciulli M; De Nicola F; Ciuffreda L; Goeman F; De Maria R; Vecchione A; Giusti R; Ciliberto G; Marchetti P; Maugeri-Saccà M
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
    Qian J; Nie W; Lu J; Zhang L; Zhang Y; Zhang B; Wang S; Hu M; Xu J; Lou Y; Dong Y; Niu Y; Yan B; Zhong R; Zhang W; Chu T; Zhong H; Han B
    Int J Cancer; 2020 Jun; 146(11):3124-3133. PubMed ID: 31583695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.
    Fang W; Ma Y; Yin JC; Hong S; Zhou H; Wang A; Wang F; Bao H; Wu X; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
    Clin Cancer Res; 2019 Aug; 25(16):5015-5026. PubMed ID: 31085721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
    Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J
    J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.